Yvonne McGrath
Chief Tech/Sci/R&D Officer at ITEOS THERAPEUTICS, INC.
Net worth: 328 600 $ as of 29/04/2024
Yvonne McGrath active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ITEOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/04/2020 | - |
Career history of Yvonne McGrath
Former positions of Yvonne McGrath
| Companies | Position | Start | End |
|---|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Director/Board Member | 30/04/2014 | 31/03/2020 |
| Chief Tech/Sci/R&D Officer | 30/04/2014 | 31/03/2020 | |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 31/12/2009 | 31/03/2014 |
Training of Yvonne McGrath
| The University of Wales | Doctorate Degree |
| Queen’S University Belfast | Undergraduate Degree |
Statistics
International
| United Kingdom | 4 |
| Belgium | 2 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
- Stock Market
- Insiders
- Yvonne McGrath
- Experience
